| | TransTech Pharma, Inc. Obtains Exclusive License to Glucokinase Activator Program for the Treatment of Diabetes From ... |
 | | The drug candidates licensed by TransTech are novel, orally administered compounds discovered during a strategic research collaboration initiated in 2001 between TransTech and Novo Nordisk utilizing TransTech's proprietary small-molecule discovery engine, TTP Translational Technology®. |
 | | Adnan Mjalli, PhD, founder, chairman and chief executive officer of TTP, said, "The promise of glucokinase activators to transform diabetes therapy is enormous. |
 | | The addition of the glucokinase activator program will greatly enhance our existing diabetes and obesity portfolio and allow TransTech to become a world leader in the discovery and development of novel treatments for diabetes and obesity -- a key therapeutic focus of the company. |
| www.redorbit.com /news/health/848978/transtech_pharma_inc_obtains_exclusive_license_to_glucokinase_activator_program/index.html?source=r_health (670 words) |